Valuation: Beta Bionics, Inc.

Market Cap 753M 652M 615M 558M 1.05B 72.14B 1.06B 7.35B 2.83B 36.6B 2.83B 2.76B 116B P/E 2026 *
-7.83x
P/E 2027 * -7.52x
Enterprise Value 619M 536M 506M 459M 861M 59.33B 868M 6.04B 2.33B 30.1B 2.32B 2.27B 95.68B EV / Sales 2026 *
4.79x
EV / Sales 2027 * 3.77x
Free-Float
98.89%
Yield 2026 *
-
Yield 2027 * -
1 week-14.04%
Current month-16.21%
1 month-4.78%
3 months+15.15%
6 months+60.69%
Current year-45.09%
1 week 15.85
Extreme 15.85
19.51
1 month 15.85
Extreme 15.85
20.66
Manager TitleAgeSince
Chief Executive Officer 50 2022-08-14
Director of Finance/CFO 37 2022-07-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 2020-01-31
Director/Board Member 50 2022-08-14
Director/Board Member 63 2024-09-30
Change 5-day change 1-year change 3-year change Capi.($)
+0.78%-14.70%-36.77% - 745M
+0.62%-0.03%+27.98%+19.00% 225B
+1.55%-2.12%+6.95%-19.82% 141B
+2.38%+3.07%-15.95%+24.43% 130B
+4.82%-5.75%-56.14%-14.87% 62.29B
+1.99%+0.96%-18.12%-13.93% 49.39B
+1.36%-4.87%+10.25%+15.54% 48.63B
-0.09%-2.69%+19.12%+27.79% 41.42B
+0.41%+0.15%+38.80%+50.73% 40.12B
+2.16%-2.35%-17.45%+51.04% 31.23B
Average +1.69%-2.00%-4.13%+15.54% 85.52B
Weighted average by Cap. +1.58%-1.31%+4.01%+11.18%

Financials

2026 *2027 *
Net sales 129M 112M 106M 95.91M 180M 12.39B 181M 1.26B 487M 6.29B 486M 475M 19.99B 180M 156M 148M 134M 251M 17.29B 253M 1.76B 679M 8.77B 678M 663M 27.88B
Net income -95.62M -82.85M -78.19M -70.93M -133M -9.16B -134M -934M -360M -4.65B -359M -351M -14.78B -99.8M -86.48M -81.61M -74.04M -139M -9.57B -140M -975M -376M -4.85B -375M -367M -15.43B
Net Debt -134M -116M -109M -99.19M -186M -12.82B -187M -1.31B -503M -6.5B -502M -491M -20.67B -73.32M -63.53M -59.96M -54.39M -102M -7.03B -103M -716M -276M -3.57B -275M -269M -11.33B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
-
Date Price Change
26-09-14 US$16.72 +0.78%
26-09-11 US$16.59 0.00%
26-09-10 US$16.59 -4.82%
26-09-09 US$17.43 -9.88%
26-09-08 US$19.34 -0.57%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
16.73USD
Average target price
21.22USD
Spread / Average Target
+26.83%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!